Not finding it? Sign in to also search OpenAlex live.
-
In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Lutz Peter Mueller, Schmid Christoph, Stefan W. Krause, +22 more
42citations -
Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis2020 bioRxiv (Cold Spring Harbor Laboratory) preprint Immunology and Microbiology Mast cells and histamine Open access
Marcelo A. S. Toledo, Malrun Gatz, Stephanie Sontag, Karoline Veronika Gleixner, Gregor Eisenwort, Kristina Feldberg, +21 more
4citations -
Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia2020 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Chronic Myeloid Leukemia Treatments Open access
Thomas Wilhelm, Marcelo A. S. Toledo, Ilka Simons, Christian Stuth, Vrinda Mohta, Ronja Isabelle Mülfarth, +7 more
0citations -
Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis2023 Clinical Epigenetics article Biochemistry, Genetics and Molecular Biology Epigenetics and DNA Methylation Open access cited by 2 patents
Ledio Bocova, Wouter H. G. Hubens, Cordula Engel, Steffen Koschmieder, Edgar Jost, Wolfgang Wagner
4citations -
STAT5-Activating Oncogenes Drive Oncostatin M Production Causing T Cell Exhaustion and Suppressive Myeloid Cell Recruitment2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Michael P. Rassner, Tony Andreas Müller, Kirstyn Anne Crossley, Geoffroy Andrieux, Lena Jakob, Alina Müller-Rudorf, +13 more
1citations -
Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)
Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg‐Nikolaus Franke, +10 more
0citations